Mylan Bids Nearly $30 Billion For Perrigo In Generic Market Consolidation Move
This article was originally published in The Tan Sheet
Perrigo receives an unsolicited offer from Mylan for almost $30 billion in cash and stock, the firms say. The deal, which would create an OTC, nutritional product and generic Rx drug firm with 2014 revenue of $15.3 billion, could launch a bidding war with other firms vying for Dublin-based Perrigo, say analysts.
You may also be interested in...
In Brief: Vitamix Expands, No “Probiotic” In E.U. Ads, Mylan Misses On Meda, Akorn Hits On VersaPharm
Vitamix triples manufacturing space; using ‘probiotic’ not allowed in E.U.; Meda rejects Mylan bids; Akorn acquires VersaPharm; La. blocks DXM sales to minors; and more news In Brief.
OTC private label leader Perrigo acquires Irish firm Elan for $8.6 billion in a deal that will bring tax savings from being incorporated in Ireland, provide a stage for European expansion and tap into Elan’s royalty rights. “Simply stated, we're going to be able to further our international platform,” CEO Joseph Papa says.
FTC pursuing bogus health and other products or services capitalizing on Covid-19 fear with scams skyrocketing. However, FTC says its enforcement will consider whether businesses are making good faith efforts to produce products in high demand.